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Research Article
Fast screening of N-glycosylation disorders
by sialotransferrin profiling with capillary
zone electrophoresis
HA Kingma, FH van der Sluijs and MR Heiner-Fokkema
Abstract
Background: Congenital disorders of glycosylation (CDG) are a growing group of rare genetic disorders. The most
frequently used screening method is sialotransferrin profiling using isoelectric focusing (IEF). Capillary zone electropho-
resis (CZE) may be a simple and fast alternative. We investigated the CapillarysTM CDT assay (Sebia, France) to screen
for N-glycosylation disorders, using IEF as gold standard.
Methods: Intra- and inter-assay precision were established, and analyses in heparin-anticoagulated plasma and serum
were compared. Accuracy was assessed by comparing IEF and CZE profiles of 153 samples, including 49 normal,
53 CDG type I, 2 CDG type II, 1 combined CDG type I and type II and 48 samples with a Tf-polymorphism.
Neuraminidase-treated plasma was analysed to discriminate CDG and Tf-polymorphisms using samples of 52 subjects
(25 had a confirmed Tf-polymorphism). Age-dependent reference values were established using profiles of 312 samples.
Results: Heparin-plasma is as suitable as serum for CDG screening with the CapillarysTM CDT assay. The precision of
the method is high, with a limit of quantification (LOQ) of 0.5%. All profiles, including CDG and Tf-polymorphisms, were
correctly identified with CZE. Forty-nine of 52 neuraminidase-treated samples correctly identified the presence/absence
of a Tf-polymorphism. Interferences in 3/52 samples hampered interpretation. Sialo-Tf profiles were dependent of age,
in particular in the first three months of age.
Conclusions: CZE analysis with the CapillarysTM CDT kit (Sebia) is a fast and reliable method for screening of
N-glycosylation defects. Tf-polymorphisms could be excluded after overnight incubation with neuraminidase.
Keywords
Congenital disorders of glycosylation, sialotransferrin, transferrin polymorphisms, neuraminidase, capillary zone
electrophoresis
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Introduction
Congenital disorders of glycosylation (CDG) are a
rapidly growing group of rare genetic disorders
caused by deficiencies in enzymes involved in the syn-
thesis or remodelling of the carbohydrate backbone of
glycoproteins and glycolipids. A total of 105 glycosyl-
ation defects have thus far been identified and the
number is growing.1,2 Recently, other forms of CDG
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have been identified with defects in vesicular traffick-
ing, pH homeostasis or Mn2þ homeostasis. CDG is
associated with broad clinical phenotypes, for an over-
view we refer to the recent review of Pe´anne et al.1
With a few exceptions, screening of defects in
N-glycosylation and combined N- and O-glycosylation
defects, leading to diminished end-standing sialic acid,
is possible by analysis of sialotransferrin (sialo-Tf)
patterns in plasma. To discriminate the isolated
N-glycosylation and combined N- and O-glycosylation
defects, additional analyses are necessary, for example
by sialo-Apo-CIII profiling. Defects in N-glycosyla-
tion are caused by defects in glycan synthesis in the
endoplasmic reticulum (CDG type I) or by defects in
the processing of the glycans, mainly in the GOLGI
(CDG type II). Transferrin (Tf) is a plasma iron trans-
port protein, with two asparagine N-glycosylation
sites, each having a maximum of four end-standing
sialic acid residues. Normally, plasma Tf consists of
tetrasialo-Tf, with small portions of penta-, tri- and
disialo-Tf. A CDG type I pattern is associated with
increased disialo- and often asialo-Tf fractions, where-
as most CDG type II are associated with overall Tf
hypoglycosylation, frequently with an increased
trisialo-Tf fraction. Combinations of CDG type I
and II patterns also exist. The most frequently used
screening method for CDG is isoelectric focusing
(IEF) in combination with immunofixation. Several
other analytical methods have been developed to ana-
lyse sialo-Tf fractions, including high-performance
liquid chromatography (HPLC), capillary zone elec-
trophoresis (CZE), or mass spectrometry (MS).3–5
CZE is a simple and fast method for sialo-Tf analysis.
Other studies have already shown that this method is
promising with regard to screening for CDG.5–12 The
Sebia CapillarysTM CDT kit is developed for diagnos-
ing alcohol abuse. In this method, Tf isoforms are
separated in silica capillaries by electrophoretic mobil-
ity and electro-osmotic flow at high voltage in an
alkaline buffer. A specific diluent is used to allow
for saturation of Tf with iron. Sialo-Tf fractions are
detected during migration by UV absorbance. The
Capillarys 2TM is fast compared with IEF; in our
experience, it is able to analyse up to 28 samples per
hour. No sample preparation is required with the
CDT kit, in contrast to other CZE methods. Until
now, only two papers appeared on the application
of this specific CDT kit for CDG screening.7,10 The
number of patients was, however, very low in both
papers, i.e. two7 and eight patients,10 respectively. In
this paper, we investigated the value of the CDT
method for screening of N-glycosylation disorders,
using IEF as gold standard and determined reference
values. In addition, we compared two sample types,
i.e. heparin-anticoagulated plasma and serum, and
investigated the possibility to confirm Tf polymor-




IEF of serum or plasma Tf was performed essentially as
described by Van Eijk and Van Noort.13 In short, 10lL
plasma was incubated with an Fe(III)-citrate solution to
saturate Tf with Fe(III). Supernatant (1lL) was subse-
quently applied on a polyacrylamide gel with a pH
gradient of 4.0–6.5 (PhastGel, GE Healthcare Bio-
Sciences). After electrophoresis (2000 V), Tf is immuno-
fixated using Rabbit antihuman Tf and coloured using
Coomassie Brilliant Blue R250.
CZE analysis
Multicapillary CZE was performed on a commercially
available system (Sebia, Capillarys 2TM, France). Seven
silica capillaries operate in parallel (effective length
17.5 cm 25 lm I.D.), and detection of the sialo-Tf
occurs with UV detection at 200 nm wavelength. All
reagents were provided in a commercial kit named
CapillarysTM CDT assay, including buffer solution,
wash solution, sample diluent and plastic consumables.
Data analysis was performed with the software pack-
age Phoresis 8.6.3 (Sebia, France).
Validation of CZE analysis
Comparison heparin-anticoagulated plasma and serum sialo-Tf
profiles. Samples of 48 subjects with normal sialo-Tf
profiles were used to compare sialo-Tf profiles in
heparin-anticoagulated plasma and in serum. Samples
were analysed and compared by Passing-Bablok regres-
sion analysis.
Intra- and inter-assay precision. Three samples were used
for precision studies: (1) commercial normal control
(Sebia, CDT), (2) a heparin-anticoagulated plasma
sample of a patient with a CDG type I profile and
(3) a heparin-anticoagulated plasma sample of an
apparently healthy person without a Tf polymorphism.
Samples were analysed in a single day (seven times;
once in each capillary) to calculate intra-assay varia-
tion and each capillary once per day for 8–10 days to
calculate inter-assay variation per capillary and their
mean variation as representative of the inter-assay var-
iation. The coefficients of variation (CV) were calculat-
ed by dividing the standard deviation by the mean
(SD/mean 100%).
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Accuracy. Accuracy was assessed by comparing IEF and
CZE profiles of 153 anonymized samples, including 49
reference samples, 48 samples of subjects with a Tf-
polymorphism, 53 samples with a CDG type I profile,
i.e. 48 samples from CDG type I patients and 5 samples
from a patient with hereditary fructose intolerance
[HFI]), 2 samples from a CDG type II patient and
1 sample from a patient with a combined CDG type I
and II pattern. The CDG type I population consisted
of 17 PMM2-CDG, 15 PMI-CDG, 6 ALG6-CDG,
6 ALG12-CDG and 3 patients with a CDG type I pro-
file (definitive genetic diagnoses not established due to
loss to follow-up). The patient with the CDG type II
pattern had no genetic diagnoses yet, but no Tf poly-
morphism was demonstrated; the profile was consistent
in all available samples and the patient had a highly
abnormal sialo-Apo-CIII profile confirming a CDG.
The patient with a combined CDG type I and II pat-
tern was diagnosed with PGM1-CDG. Most samples
with a Tf-polymorphism or with CDG type I and/or II
profiles were previously examined by IEF and reana-
lysed with CZE. These samples were stored deep frozen
for a maximum period of 15 years in 80C. The other
data derived from patients suspected of a CDG, whose
samples were prospectively analysed in the context of
diagnostic procedures with both IEF and CZE.
Reference values. Reference values were calculated using
312 samples analysed by CZE with a normal sialo-Tf
profile. Samples derived from patients whose samples
were analysed in the context of diagnostic procedures.
Age dependency was assessed by Spearman Rank tests
(at P< 0.05), and by visual inspection of the relation
between age and sialo-Tf fraction. Ninety-five per cent
reference values were calculated as 2.5 to 97.5
percentiles.
Neuraminidase treatment. An additional set of 52 sam-
ples were treated with neuraminidase, of which
25 had a Tf polymorphism on IEF (25 controls) and
27 had no Tf polymorphism on IEF (17 CDG patients,
10 controls). Heparin-anticoagulated plasma samples
(90 lL) were incubated at room temperature
(20–25C) overnight with 10 lL (5U/110 lL
MilliQ water) neuraminidase (Roche Diagnostics
International Ltd, Mannheim, Germany). Samples
were analysed with CZE and qualitatively compared
with results produced earlier with IEF. We did not
aim to fully characterize the Tf-polymorphisms.
Ethical statement. The conducted research is not related
to human use as meant in the Medical Research involv-
ing Human Subjects Act, since we made use of coded
samples that were already used for similar diagnostic
purposes. The study design was in accordance with the
current revision of the Helsinki Declaration.
Results
Comparison between heparin-anticoagulated plasma
and serum CZE profiles
No significant bias was found between serum and
heparin-anticoagulated plasma samples (n¼ 48) by
Passing-Bablok analyses (P< 0.05). The correlation
coefficients were 0.988 (pentasialotransferrin [S5-Tf]),
0.990 (tetrasialotransferrin [S4-Tf]), 0.998 (trisialo-
transferrin [S3-Tf]) and 0.932 (disialotransferrin [S2-
Tf]). Percentages of monosialotransferrin (S1-Tf) and
asialotransferrin (S0-Tf) fractions were too low for sta-
tistical analyses.
Intra- and inter-assay precision
Intra- and inter-assay precision are presented in
Table 1. Sialo-Tf fractions had coefficients of variation
(CV) between 0.1% and 19.6%. The CV was mainly
dependent on the amount (percentage) of sialo-Tf pre-
sent in the sample. The S5-Tf fraction had relatively
high inter-assay variability compared with other frac-
tions at similar amounts (percentages) present.
Fractions below 0.5% seem to reach the limit of quan-
tification (LOQ) defined as an imprecision >20%.
Accuracy
Figure 1 (left) shows six examples of the various pat-
terns analysed in our sample set, e.g. profiles of a con-
trol (1a), two CDG type I patients (1b and 1c), a CDG
type II patient (1d) and two subjects with a Tf poly-
morphism (1e, 1f).
Of the 153 plasma samples that were analysed with
both IEF and CZE, 105 samples could be quantified,
i.e. 49 samples with a normal pattern (S0-Tf range:
0.0–0.4%, S1-Tf 0.0–0.0%, S2-Tf 0.0–1.1%, S3-Tf
0.0–12.8%, S4-Tf 72.6–99.1%, S5-Tf 0.9–20.0%), 45
samples of CDG type I and HFI patients (S0-Tf
range: 0.0–38.2%, S1-Tf 0.0–1.4%, S2-Tf 3.1–53.7%,
S3-Tf 0.0–8.4%, S4-Tf 10.2–90.7%, S5-Tf 1.4–21.3%),
8 samples of PMI-CDG (n¼ 3) and HFI (n¼ 1)
patients under treatment, i.e. liver transplant or man-
nose for PMI-CDG and fructose- and sucrose-free diet
for HFI (S0-Tf range 0.0–0.0%, S1-Tf 0.0–0.0%, S2-Tf
0.4–3.0%, S3-Tf 1.6–8.7%, S4-Tf 74.6–82.5%, S5-Tf
12.5–17.6%), 2 samples of a CDG type II patient
(S0-Tf range 0.0–0.0%, S1-Tf 0.0–0.0%, S2-Tf
2.6–2.7%, S3-Tf 26.8–27.8%, S4-Tf 58.3–61.0%,
S5-Tf 8.5–12.3%) and 1 sample of a PGM1-CDG
patient with a combined CDG type I and II profile
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(S0-Tf range 2.5%, S1-Tf 0.0%, S2-Tf 10.3%, S3-Tf
9.6%, S4-Tf 62.3%, S5-Tf 15.3%). In these 105 sam-
ples, all without Tf-polymorphisms, significant biases
between CZE and IEF were found for all fractions,
except for S0-Tf (r¼ 0.947). Bias and correlation coef-
ficients (r) were as follows: S5-Tf
(CZE¼ 0.53IEFþ 3.5, r¼ 0.627), S4-Tf
(CZE¼ 1.18IEF, r¼ 0.891), S3-Tf (CZE¼
0.61IEF1.4, r¼ 0.893) and S2-Tf (CZE¼ 0.89
IEF1.8, r¼ 0.968). S1-Tf was absent in most samples,
and therefore statistical analyses were not possible for
this fraction. All CDG patients had abnormal profiles
with both IEF and CZE, and all controls had normal
profiles with both methods; diagnostic accuracy
of CZE compared with IEF was 100%. Tf-
polymorphisms (n¼ 48) were left out in these analyses,
because sialo-Tf fractions could not be quantified.
Tf polymorphisms were recognized with both CZE
and IEF, but eluted differently. With IEF, three poly-
morphisms were identified in our samples, with the
S4-Tf variant appearing nearby S5 (n¼ 28), S3
(n¼ 17) or S0 (n¼ 3). The variant eluting nearby
S5-Tf with IEF appeared nearby S3-Tf with CZE
(data not shown). The variant eluting nearby S3-Tf
with IEF eluted with CZE nearby S2 (n¼ 11/17, see
Figure 1(e)) or S3 (n¼ 6/17, see Figure 1(f)). This sep-
aration probably results from separation of the differ-
ent so-called Tf-D variants, as demonstrated by
Caslavska et al.14 The variant S4-Tf that eluted at
S0 position with IEF was not detected with CZE
(a normal profile was shown).
Neuraminidase treatment
Figure 1 (right) shows profiles of five samples after
treatment with neuraminidase. Samples before and
after neuraminidase treatment are displayed in the
same row, i.e. Figure 1(a0) is the neuraminidase-
treated sample of Figure 1(a). Unfortunately, there
was not enough sample left to perform neuraminidase
treatment on sample 1C (CDG type II).
Fifty-two samples were treated with neuraminidase,
of which 27 had no polymorphism. In 25 of these 27
samples, either with a normal pattern (Figure 1(a)) or a
CDG type I pattern (Figure 1(b)), a single peak migrat-
ing cathodic to S0-Tf appeared after neuraminidase
treatment (Figure 1(a0) and (b0)). In 2/27 samples, an
interfering compound appeared. In four samples, all of
confirmed CDG patients with a relatively large
S0-fraction, two co-eluting peaks were shown (see
Figure 1(c0)). All other samples showed a single peak.
In 24/25 samples with a Tf polymorphism (Figure 1(e)
and (f)), two baseline-separated peaks migrating
cathodic to S0-Tf appeared after neuraminidase treat-
ment (Figure 1(e0) and (f0)), demonstrating the presence
of a Tf variant. Interpretation of the profile was not
possible in 1/25, because of an interfering compound
eluting nearby asialo-Tf.
CZE and IEF in a patient with a mildly abnormal
CDG type I pattern
Figure 2 shows CZE and IEF profiles of an ALG12-
CDG (CDG-1g) patient at 3 days and 46 days of age
(neuraminidase profiles were normal), demonstrating
the accuracy of the CZE method in diagnosing mild
CDG profiles. The CZE profile was clearly abnormal
at both days 3 and 46, whereas the IEF profile at day 3
was less pronounced. The S2-Tf fraction with IEF was
2.4 times the upper reference limit (URL), whereas it
was 8.3 times the URL with CZE.
Table 1. Intra- and interday precision of sialotransferrin fractions with CZE.
Sample
S5-Tf S4-Tf S3-Tf S2-Tf S1-Tf S0-Tf





























































Note: Sialo-Tf fractions are notated as S5-Tf to S0-Tf.
aOf the CDG type I sample, 11 samples were analysed for CVa-inter for capillaries 1,3,6 and 10 samples for capillaries 2,4,5,7.
CVa-intra: intra-assay variation; CVa-inter: inter-assay variation; Numbers (N) represent numbers for CVa-intra/numbers for CVa-inter.
Values represent mean fractions (sialo-Tf %) and in parentheses the corresponding variation coefficients (CV%).
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Figure 1. Examples of sialo-Tf profiles with CZE.
Sialotransferrin (Sialo-Tf) profiles with capillary zone electrophoresis (CZE) before (left) and after neuraminidase treatment (right).
The isoelectric focusing (IEF) patterns of the samples are presented in the small lanes. Sialo-Tf fractions are notated as S0 for asialo-Tf,
S2 for disialo-Tf and so on. The variant S4 is notated as S4var. a: Control sialo-Tf profile in heparin-anticoagulated plasma or serum; a’:
Control sialo-Tf profile after neuraminidase treatment; b: CDG type I profile; b’: CDG type I profile after neuraminidase treatment; c:
CDG type I profile; c’: CDG type I profile after neuraminidase treatment; d: CDG type II profile; e: Tf polymorphism (variant Tf at S2-
position with CZE); e’: Tf polymorphism (variant Tf at S2-position with CZE) after neuraminidase treatment; f: Tf polymorphism
(variant Tf at S3-position with CZE); f ’: Tf polymorphism (variant Tf at S3-position with CZE) after neuraminidase treatment.
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Reference values
The mean (range) age of the reference group (n¼ 312)
with normal profiles was 5.7 (0.0–52.5) years. Sialo-Tf
fractions were significantly age dependent mainly in
children below three months of age. After this age,
S4- and S3-Tf fractions slightly increased at the expense
of S5-Tf and some S2-Tf until approximately the age of
5 years, but this did not affect the upper limits of the
reference values to a clinically significant extent. We
decided to calculate the reference values for all ages,
using 2.5 and 97.5 percentiles, see Table 2.
Discussion
We investigated the value of the CDT method
for screening of N-glycosylation disorders, using IEF
as gold standard, and determined reference values.
We additionally compared the use of heparin-
anticoagulated plasma with serum and the possibility
to investigate Tf polymorphisms with CZE after treat-
ment of plasma with neuraminidase.
At this moment, IEF is the most common applied
method to screen for N-glycosylation and combined
N- and O-glycosylation defects.4 Our results showed
that CZE with the CDT method is a good and simple
alternative for CDG screening compared with IEF. The
method requires much less hands-on time compared
with IEF. All abnormal profiles, i.e. CDG or Tf-
day 3
day 46
CZE IEF Fracon CZE day 3 IEF day 3 
S6-Tf n.d. 2 %
S5-Tf 4.1 % 7 %
S4-Tf 80.5 % 68 %
S3-Tf 6.3 % 9 %
S2-Tf 9.1 % 12 %
S1-Tf 0.0 % 1 %
S0-Tf 0.0 % 1 %
Fracon CZE day 46 IEF day 46
S6-Tf n.d. 2 %
S5-Tf 11.2 % 9 %
S4-Tf 66.4 % 61 %
S3-Tf 3.4 % 5 %
S2-Tf 18.8 % 22 %
S1-Tf 0.0 % 0 %



















Figure 2. CZE and IEF sialo-Tf profiles of CDG type I patient.
Capillary zone electrophoresis (CZE) and isoelectric focusing (IEF) sialo-Tf profiles of a CDG type I (ALG12-CDG) patient at 3- and
46-days of age, together with quantitation of the sialo-Tf fractions. Abnormalities progress with age. Reference values for CZE, see
Table 2. Reference values for IEF: S6-Tf (1–5%), S5-Tf (10–25%), S4-Tf (60–80%), S3-Tf (1–12%), S2-Tf (1–5%), S1-Tf (0–0%) and S0-Tf
(0–0%).
Table 2. Reference values of Tf-fractions with CZE.







S0-Tf: asialotransferrin; S1-Tf: monosialotransferrin; S2-Tf: disialotrans-
ferrin; S3-Tf: trisialotransferrin; S4-Tf: tetrasialotransferrin; S5-Tf:
pentasialotransferrin.
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polymorphisms, were correctly identified with CZE,
using heparin-anticoagulated plasma. The precision of
the method is high. Hexasialotransferrin (S6-Tf), often
visible when analysing samples with IEF, could not be
detected with certainty with the Sebia CZE method.
The precision of the method decreases when fractions
drop below 1%, and the LOQ is reached when frac-
tions are below 0.5%. The precision of the CZE
method is better compared with the precision with
our IEF method, which has CVs varying from 3.0%
for high abundant fractions (70%) to 36% for low
abundant fractions (1.4%), with an LOQ of approxi-
mately 6%. CZE has therefore at least similar sensitiv-
ity to recognize so-called mild CDG type I profiles.
This is further illustrated by the results of a plasma
sample with a mild CDG type I profile, see Figure 2.
Earlier reports showed that the precision of CZE with
the Capillarys 2TM of Sebia is also one of the highest
compared with other CDT methods.15
Even though CDG screening is possible with this
readily available technique, screening of these rare
inborn errors should always be an integral part of met-
abolic screening in genetic metabolic laboratories.
CDG screening alone is never sufficient to screen for
patients with the aspecific symptoms that accompany
these different diseases. There are only a very few CDG
types whose symptoms may directly point at a CDG,
and also in these patients, abnormal screening should
always be confirmed in specialized laboratories.
Heparin- or EDTA-anticoagulated plasma is most
often applied in genetic metabolic laboratories. Use
of EDTA-plasma is not recommended by Sebia.
From the relations between serum and heparin-
anticoagulated plasma in normal profiles, and from
the agreement between CE and IEF methods in
patients and controls with heparin-anticoagulated
plasma, we showed that heparin-anticoagulated
plasma is as good as serum for screening with the
CDT method, i.e. heparin did not invalidate quantifi-
cation of (low) sialo-Tf fractions.
It was previously suggested that CZE is a good alter-
native to IEF for CDG screening.6–12 The largest study
performed thus far on the use of CZE for CDG screen-
ing was performed by Carchon et al.6 They demon-
strated in 792 CZE analyses using the CEofixTM-
CDT kit (Analis, Namur, Belgium) on a Beckmann
Coulter P/ACE 5000 system that all abnormal profiles
and confirmed CDG samples were correctly identified
by CZE. Only two papers have previously analysed the
performance of the CDT kit for CDG screening on a
Sebia CapillarysTM,7,10 and both papers showed that
CDG patients were correctly identified with the CDT
kit; however, the number of patients investigated was
very low, i.e. two7 and eight,10 respectively. Our results
with a larger population of CDG patients are in
agreement with the good performance for analysing
CDG. The Capillarys CDT method has the advantage
above the CEofixTM-CDT kit that iron saturation is
not necessary before loading the sample on the capillar-
ies, thereby reducing sampling handling and increasing
automation.7,10
An important factor to consider when analysing
sialoTf-fractions is the existence of Tf (micro)heteroge-
neity due to Tf polymorphisms. These polymorphisms
affect the isoelectric point of Tf, and therefore interfere
with the interpretation of sialo-Tf profiles.4 In CZE,
these polymorphisms also hamper interpretation, in
particular since the profiles seem comparable to CDG
profiles (also see Figure 1). The S4-Tf variant appear-
ing at S2-Tf with CZE (see Figure 1(e)) might be con-
fused with a CDG type I profile (Figure 1(b) and (c)),
in particular in CDG patients with an absent S0-Tf
fraction. These profiles may be differentiated in most
samples by the variant S3-Tf appearing at the S1-Tf
position in Tf polymorphisms only. The S4-Tf appear-
ing at the S3-Tf position with CZE (Figure 1(f)) is
highly comparable to the pattern of the CDG type II
patient, a very rare group of disorders (Figure 1(d)).
The ratio of the S4-Tf and the variant S4-Tf may give a
clue to diagnoses, since in (most) Tf polymorphisms,
the ratio is approximately 50%. There are however
exceptions, because of mixed profiles in the presence
of a Tf variant. To differentiate a CDG type I or a
mixed CDG type I and II profile from a Tf polymor-
phism with certainty, we recommend to repeat the
analysis after incubation of plasma with neuramini-
dase. With IEF analysis, it is already good practice to
re-examine abnormal sialo-Tf profiles after incubation
of serum or plasma with neuraminidase to investigate
whether the abnormalities are due to a Tf polymor-
phism.4 Neuraminidase cleaves sialic acid groups of
Tf, leaving only asialo-Tf fractions. In case of a hetero-
zygous Tf polymorphism, two bands instead of one
appear, proving that the abnormal profile was at least
partly due to a Tf polymorphism. Two papers were
published, showing the potential to characterize Tf
polymorphisms with CZE using the CEofixTM-CDT
kit (Analis, Belgium) on a PA800 CE system
of Beckman Coulter (Fullerton, CA, USA).14,16
Identification of the specific Tf variant was not the
aim of our study, we were particularly interested to
see if neuraminidase treatment could differentiate the
Tf polymorphisms from the CDG patients. In this way,
a reduction in the number of patients who need CDG
confirmation and subtype specification in specialized
laboratories can be achieved. We showed that Tf poly-
morphisms could indeed be differentiated from CDG
profiles when analysing neuraminidase-treated samples
with the Sebia CDT kit on the Capillarys 2TM. Three
samples showed an interference (only) after treatment
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with neuraminidase. These profiles could not be inter-
preted and should be reanalysed using an alternative
method. No such interferences were shown in samples
that were stored up to three weeks; it is as yet unknown
if the interferences are due to degradation of proteins
during long-term storage of the samples. In theory,
a Tf-polymorphism may be present in a patient with
a CDG. In case of doubt, analysis with an alternative
method to confirm the presence of a CDG, for example
mass-spectrometry, may be necessary. Interestingly, in
CDG type I patients, two co-eluting S0-fractions are
present after neuraminidase treatment. This effect is
most pronounced in samples with relatively high
asialo-Tf. The two fractions after neuraminidase treat-
ment seem to appear in CDG type I patients only,
probably because naturally occurring asialo-Tf without
glycan chains is present next to the neuraminidase
cleaved Tf with glycan chains. The absence of glycan
chains is likely to affect electrophoretic behaviour.
Quantitative differences between IEF and CZE
methods exist; therefore, specific reference values for
CZE need to be determined. The current method is
sensitive even at low sialo-Tf fractions revealing a rela-
tion between plasma sialo-Tf fractions and age, in par-
ticular in the first year of life. Most remarkably, S3-Tf
and S5-Tf increase with age, as previously shown by
Zamboni et al.12 Changing serum N-glycan profiles
with age is already known,17 although the physiology
is not yet completely understood.
The main limitation of the CZE method is the occur-
rence of mainly unknown interferences, because of the
non-specific detection of compounds (mainly peptide
bonds) at 200 nm. According to the manual of the
CapillarysTM CDT assay, immunoglobulins (appearing
anodic to S0-Tf), C-reactive protein, C3d protein due
to complement 3 degradation (appearing cathodic to
S5-Tf), haemolysis, high fibrinogen and substances in
samples of patients with severe liver disease also inter-
fere. Interferences were also found in samples of
patients with several types of cancer, including lung,
breast and colorectal carcinoma.18 Total bilirubin,
triglycerides, cholesterol and haemoglobin did not
interfere up to concentrations of 256.5 lmol/L,
9.41mmol/L, 10.87 mmol/L and 1.5 g/L, respectively.19
To diminish the effects of interferences, Sebia provides
a treatment reagent. No interferences hampering inter-
pretation were identified in the analysed samples (with-
out neuraminidase treatment). In case such an
interference appears, we recommend reanalysing sam-
ples with IEF or N-glycan mass-spectrometry. All sam-
ples with CDG type I and/or type II profiles should
also be confirmed enzymatically or genetically by
follow-up testing in reference laboratories.
We conclude that CZE is a fast and reliable method
for screening of N-glycosylation defects in serum or
heparin anticoagulated plasma samples. Samples can
be investigated with CZE for Tf polymorphisms after
overnight incubation with neuraminidase.
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